The author concluded that rapamycin effectively eliminates leukemia blast but fails to inhibit mTOR in leukemia stem cells, which could contribute to the limited clinical efficacy of rapamycin in T-ALL [124]. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.